About two-thirds of urologists own electronic prescribing systems, placing urology second among specialties in e-prescribing adoption, according to a study that tracked adoption rates between 2007 and 2010.
About two-thirds of urologists own electronic prescribing systems, placing urology second among specialties in e-prescribing adoption, according to a study that tracked adoption rates between 2007 and 2010.
E-prescribing ownership significantly increased among physician practices overall during the period, according to the study, which was published online in the American Journal of Pharmacy Benefits (Dec. 12, 2013).
For the study, researchers examined data from the National Ambulatory Medical Care Survey between 2007 and 2010. Respondents were asked about their e-prescribing tools and how they used such systems. Overall, the percentage of physicians who owned e-prescribing tools increased from 29.9% in 2007 to 56.4% in 2010.
The top three specialties for owning e-prescribing tools in 2010 were general and family medicine (68.4%), urology (65.5%), and cardiology (64.9%). E-prescribing adoption among urologists may actually be higher. The 2013 Urology Times State of the Specialty survey found that 87% of urologists use e-prescribing, and the number is even higher-98%-among those in groups of 10 or more urologists.
“Electronic prescribing access is growing, although use in certain specialties lags behind others,” wrote the authors, led by Erik Kokkonen, MD, of Wake Forest University, Winston-Salem, NC. “Solo practitioners, owners of practices, and physicians outside metropolitan areas also may require expanded incentives to adopt e-prescribing.”
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.